---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-003502"
form_type: "8-K"
ticker: "MLYS"
cik: "0001933414"
company_name: "Mineralys Therapeutics, Inc."
filed_at: "2023-02-14T23:59:59+00:00"
generated_at: "2026-06-19T14:40:30.741052+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Mineralys Therapeutics closes IPO of 13.8M shares at $16, raising $220.8M

## Summary
- Completed IPO of 13,800,000 shares (including full exercise of underwriters' option) at $16.00 per share.
- Gross proceeds of $220.8 million before underwriting discounts and offering expenses.
- Filed amended charter increasing authorized common stock to 500M shares and authorizing 50M shares of preferred stock.

## SEC filing metadata
- accession: 0001628280-23-003502
- form_type: 8-K
- ticker: MLYS
- cik: 0001933414
- company_name: Mineralys Therapeutics, Inc.
- filed_at: 2023-02-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1933414/000162828023003502/0001628280-23-003502-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1933414/000162828023003502/mineralys-8xk.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-003502
- JSON: https://secwatch.observer/filing/0001628280-23-003502.json
- Plain text: https://secwatch.observer/filing/0001628280-23-003502.txt

## Key facts
- Governance Changes
  Mineralys Therapeutics, Inc.: Filed amended and restated certificate of incorporation upon IPO closing, increasing authorized common stock to 500M shares, authorizing 50M undesignated preferred shares, establishing a classified board, requiring cause for director removal, and eliminating stockholder action by written consent (effective 2023-02-14).
  - Change: charter amendment
  - Effective: 2023-02-14
  source text: On February 14, 2023, Mineralys Therapeutics, Inc. (the “Company”) filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the initial public offering (the “IPO”) of shares of its common stock.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1933414/000162828023003502/0001628280-23-003502-index.htm
- Governance Changes
  Mineralys Therapeutics, Inc.: Amended and restated bylaws to establish procedures for stockholder proposals and director nominations, and conform to amended charter (effective 2023-02-14).
  - Change: bylaw amendment
  - Effective: 2023-02-14
  source text: On February 14, 2023, in connection with the closing of the IPO, the amended and restated bylaws of the Company (the “Amended and Restated Bylaws”), previously approved by the Company’s board of directors to become effective upon the effectiveness of the Restated Certificate, became effective.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1933414/000162828023003502/0001628280-23-003502-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.